Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of HEC96719 in Healthy Subjects
NCT04422496Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) comparing HEC96719 with Placebo (2 arms). Primary endpoint: Adverse event. Started Aug 2020; status: completed.
02
Drugs
hec96719
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04422496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422496.